Association between PD-L1 expression and initial brain metastasis in patients with non-small cell lung cancer and its clinical implications

Kyoungmin Lee1 | Yoon J. Choi2 | Jung S. Kim3 | Dae S. Kim1 | Sung Y. Lee4 | Bong K. Shin5 | Eun J. Kang1

1Division of Hemato-oncology, Department of Internal Medicine, Korea University College of Medicine, Korea University Guro Hospital, Seoul, South Korea
2Division of Hemato-oncology, Department of Internal Medicine, Korea University College of Medicine, Korea University Anam Hospital, Seoul, South Korea
3Division of Hemato-oncology, Department of Internal Medicine, Korea University College of Medicine, Korea University Ansan Hospital, Seoul, South Korea
4Division of Pulmonology, Department of Internal Medicine, Korea University College of Medicine, Korea University Guro Hospital, Seoul, South Korea
5Department of Pathology, Korea University College of Medicine, Korea University Guro Hospital, Seoul, South Korea

Correspondence
Eun J. Kang, Division of Hemato-oncology, Department of Internal Medicine, Korea University College of Medicine, Korea University Guro Hospital, 148, Gurodong-ro, Guro-gu, Seoul 08308, South Korea. Email: kkangju11@naver.com

Funding information
Korea University, Grant/Award Number: K1609621

Abstract

Background: Brain metastases frequently occur in patients with non-small cell lung cancer (NSCLC) resulting in a poor prognosis. Here, we investigated the association between PD-L1 expression and brain metastasis in patients with NSCLC and its clinical significance.

Methods: A total of 270 patients diagnosed with metastatic NSCLC who underwent PD-L1 testing on their tumor tissue between January 2017 and March 2019 were retrospectively reviewed. The VENTANA PD-L1 (SP263) assay was used, and positive PD-L1 expression was defined as staining in ≥1% of tumor cells.

Results: Positive PD-L1 expression was observed in 181 (67.0%) patients, and 74 (27.4%) patients had brain metastasis at diagnosis. Synchronous brain metastases were more frequently observed in PD-L1-positive compared with PD-L1-negative patients (31.5% vs. 19.1%, p = 0.045). Multiple logistic regression analysis identified positive PD-L1 expression (odds ratio [OR]: 2.24, p = 0.012) as an independent factor associated with synchronous brain metastasis, along with the histological subtype of nonsquamous cell carcinoma (OR: 2.84, p = 0.003). However, the incidence of central nervous system (CNS) progression was not associated with PD-L1 positivity, with a two-year cumulative CNS progression rate of 26.3% and 28.4% in PD-L1-positive and PD-L1-negative patients, respectively (log rank p = 0.944). Furthermore, positive PD-L1 expression did not affect CNS progression or overall survival in patients with synchronous brain metastasis (log rank p = 0.513 and 0.592, respectively).

Conclusions: Initial brain metastases are common in NSCLC patients with positive PD-L1 expression. Further studies are necessary to understand the relationship between early brain metastasis and cancer immunity.

KEYWORDS
brain metastasis, non-small cell lung cancer, PD-L1, prognosis, screening

INTRODUCTION

Lung cancer remains the most common cause of cancer-related deaths worldwide, but it is also a cancer that has experienced the greatest advances in treatment. Non-small cell lung cancer (NSCLC) has become a prominent example of the success of precision medicine among solid tumor malignancies.1 Treatment has been increasingly driven by molecular characteristics of the tumors,2 and identifying a molecular profile from biopsied tissue for each patient during diagnosis is an essential step in establishing a treatment plan and for predicting patient outcome.

The success of programmed death protein 1 (PD-1) and programmed death-ligand 1 (PD-L1) targeted therapies has
led to interest in immune inhibitory factors as targets for NSCLC therapy. The expression of PD-L1 in cancer cells has become an important marker to consider for treatment decisions despite its ambiguous validity. In addition to its predictive role, there have been several attempts to identify the clinical characteristics of tumors by PD-L1 expression, with a particular focus on its prognostic role. Despite controversial results with regard to histological subtype and preset cutoff values, several studies have shown that positive PD-L1 expression is correlated with poor prognosis in patients with NSCLC.

Typically, brain metastases result in a poor prognosis for most solid tumors, and the lung represents the most common primary tumor site for brain metastasis. Brain metastases occur in approximately 25% of patients at the diagnostic phase of NSCLC, and almost half of the patients will eventually develop brain metastasis during disease progression. NSCLC patients with brain metastasis develop significant morbidity and mortality, although prognosis can vary depending on the molecular subtype of the patient, with median overall survival (OS) ranging from 3 to 15 months. There have been many studies regarding the risk factors that predict the development of brain metastasis in patients with NSCLC, however, little is known about the association between PD-L1 expression and brain metastasis. The purpose of this study is to investigate the correlation and clinical significance of PD-L1 expression and brain metastasis in NSCLC patients.

METHODS

Study population

We retrospectively reviewed patient records of a consecutive cohort of patients who were diagnosed with metastatic NSCLC and underwent PD-L1 testing on their tumor tissue at the Korea University Guro Hospital, Seoul, Republic of Korea, between January 2017 and March 2019. Patients found to have recurrence or metastases after treatment for early stage NSCLC were not included in the study. All patients suspected of having lung cancer underwent brain magnetic resonance imaging (MRI) for staging work-up at the time of diagnosis. Information on initial brain metastasis could therefore be retrieved from all lung cancer patients. In the case of patients with initial brain metastasis, brain MRI was performed every 3 to 6 months after treatment for brain metastasis as determined by the physician. In patients without initial brain metastasis, brain MRI was performed when there was a suspicion of new onset of brain metastasis during systemic treatment.

Data collected from the electronic medical records included clinicopathological variables such as patient demographics, smoking status, site of metastatic lesions, histopathological characteristics, and molecular subtypes, including anaplastic lymphoma kinase (ALK) gene rearrangement and epidermal growth factor receptor (EGFR) gene mutation status. Data for therapeutic regimen and treatment response were also collected, and tumor response was graded according to the Response Evaluation Criteria in Solid Tumors version 1.1.

This study was approved by the Institutional Review Board of the Korea University Guro Hospital (IRB number 2019GR0370) and conducted in accordance with the Declaration of Helsinki and the Guidelines for Good Clinical Practice.

PD-L1 immunohistochemistry

All patients diagnosed with metastatic NSCLC in Korea have been tested for PD-L1 since 2017, because positive PD-L1 expression was used as a criterion for medical reimbursement of anti-PD-1 or PD-L1 antibodies.

For PD-L1 testing, formalin-fixed, paraffin-embedded biopsy specimens of the primary tumors were subjected to immunohistochemical analysis. The entire tumor section was used to account for PD-L1 expression heterogeneity. The sections were stained with an anti-PD-L1 (SP263, Ventana Medical Systems) rabbit monoclonal primary antibody using the OptiView DAB immunohistochemistry (IHC) detection kit on a BenchMark XT automated staining platform, according to the manufacturer’s instructions. The proportion of tumor cells with positive membranous staining (tumor proportion score, TPS) was assessed, and positive PD-L1 expression was defined as staining in ≥1% of the tumor cells. In our institution, the reproducibility of staining results was maintained through regular quality control processes, and the staining result of each patient was finally reported after being reviewed by two pathologists.

Statistical analysis

Descriptive statistics were analyzed for the demographic and clinicopathological characteristics of patients. Univariate and multiple logistic regression analyses using the backward elimination method were performed to determine the independent effects of PD-L1 positivity on the presence of brain metastasis and to find the risk factors associated with brain metastasis at diagnosis of NSCLC. The results were reported as an odds ratio (OR) with a 95% confidence interval (CI).

Central nervous system (CNS) progression was defined as progression of existing brain metastases or newly developed CNS metastases in the brain, meninges, and cerebrospinal fluid during treatment. Time to CNS progression was calculated from the date of the initial diagnosis of metastatic NSCLC to the date of first CNS progression, whereas deaths were censored. OS was calculated from the first day of diagnosis to the day of death from any cause. Survival analysis was based on all data available until the cutoff date of February 28, 2021.
Survival curves were estimated using the Kaplan–Meier method and compared using the log-rank test. The follow-up duration was described as median values based on the reverse Kaplan–Meier estimator. All statistical analyses were performed using IBM SPSS Statistics for Windows, Version 20.0 (IBM Corp.), and survival curves were generated using GraphPad Prism 5.0 (GraphPad Software). A $p$-value of $<0.05$ was considered statistically significant.

### TABLE 1  Baseline characteristics of all patients

|                          | Total ($N = 270$) | Synchronous brain metastasis |
|--------------------------|-------------------|-----------------------------|
|                          | No ($N = 196$)    | Yes ($N = 74$)              | $p$-value     |
| **Sex**                  |                   |                             |               |
| Male                     | 187 (69.3%)       | 139 (70.9%)                 | 48 (64.9%)    | 0.416 |
| Female                   | 83 (30.7%)        | 57 (29.1%)                  | 26 (35.1%)    |     |
| **Age at diagnosis**     | 71.0 (63.0; 77.0) | 72.0 (64.0; 77.0)           | 70.0 (62.0; 77.0) | 0.476 |
| **Smoking history**      |                   |                             |               |
| Never smoker             | 131 (48.5%)       | 89 (45.4%)                  | 42 (56.8%)    | 0.127 |
| Smoker                   | 139 (51.5%)       | 107 (54.6%)                 | 32 (43.2%)    |     |
| Ex-smoker                | 81 (30.0%)        | 67 (34.2%)                  | 14 (18.9%)    |     |
| Current-smoker           | 58 (21.5%)        | 40 (20.4%)                  | 18 (24.3%)    |     |
| **Histology**            |                   |                             |               |
| ADC                      | 173 (64.1%)       | 116 (59.2%)                 | 57 (77.0%)    | 0.010 |
| SqCC                     | 76 (28.1%)        | 64 (32.7%)                  | 12 (16.2%)    | 0.012 |
| Large cell NEC           | 3 (1.1%)          | 3 (1.5%)                    | 0 (0.0%)      | 0.564 |
| Others                   | 18 (6.7%)         | 13 (6.6%)                   | 5 (6.8%)      | 1.000 |
| **EGFR mutation**        |                   |                             |               |
| Mutation                 | 64 (23.7%)        | 41 (20.9%)                  | 23 (31.1%)    | 0.112 |
| Exon 19 del              | 39 (14.4%)        | 27 (13.8%)                  | 12 (16.2%)    |     |
| L858R                    | 20 (7.4%)         | 12 (6.1%)                   | 8 (10.8%)     |     |
| L858R + others           | 1 (0.4%)          | 0 (0.0%)                    | 1 (1.4%)      |     |
| Other rare mutation      | 4 (1.5%)          | 2 (1.0%)                    | 2 (2.7%)      |     |
| Wild-type                | 123 (45.6%)       | 87 (44.4%)                  | 36 (48.6%)    | 0.624 |
| Not available            | 83 (30.7%)        | 68 (34.7%)                  | 15 (20.3%)    | 0.032 |
| **ALK rearrangement**    |                   |                             |               |
| Rearrangement            | 6 (2.2%)          | 5 (2.6%)                    | 1 (1.4%)      | 1.000 |
| Wild-type                | 176 (65.2%)       | 117 (59.7%)                 | 59 (79.7%)    | 0.003 |
| Not available            | 88 (32.6%)        | 74 (37.8%)                  | 14 (18.9%)    | 0.005 |
| **PD-L1 expression**     |                   |                             |               |
| Positive (>1%)           | 181 (67.0%)       | 124 (63.3%)                 | 57 (77.0%)    | 0.045 |
| 1%–9%                    | 57 (21.1%)        | 40 (20.4%)                  | 17 (23.0%)    |     |
| 10%–49%                  | 47 (17.4%)        | 33 (16.8%)                  | 14 (18.9%)    |     |
| ≥50%                     | 77 (28.5%)        | 51 (26.0%)                  | 26 (35.1%)    |     |
| Negative (0%)            | 89 (33.0%)        | 72 (36.7%)                  | 17 (23.0%)    |     |

Abbreviations: ADC, adenocarcinoma; ALK, anaplastic lymphoma receptor tyrosine kinase; EGFR, epidermal growth factor receptor; N, number; NEC, neuroendocrine carcinoma; PD-L1, programmed death-ligand 1; SqCC, squamous cell carcinoma.

### TABLE 2  Incidence of initial brain metastasis according to histology and PD-L1 status

| PD-L1 status | Total ($N = 270$) | Non-SqCC ($N = 194$) | SqCC ($N = 76$) | $p$-value |
|--------------|-------------------|----------------------|-----------------|-----------|
|              | <1% ($N = 89$)    | ≥1% ($N = 181$)      | <1% ($N = 72$)  | ≥1% ($N = 122$) | <1% ($N = 17$) | ≥1% ($N = 59$) | $p$-value |
| Brain metastasis at diagnosis | 17 (19.1%) | 57 (31.5%) | 16 (22.2%) | 46 (37.7%) | 1 (5.9%) | 11 (18.6%) | 0.279 |

Abbreviations: N, number; PD-L1, programmed death-ligand 1; SqCC, squamous cell carcinoma.
RESULTS

Patient characteristics

A total of 270 patients who were diagnosed with metastatic lung cancer were included in this study. The median patient age was 71 years (interquartile range, 63–77) at the time of diagnosis, and 186 (68.9%) patients were male. There were 131 (48.5%) patients who had never smoked, and 139 (51.5%) patients, including 81 ex-smokers, had a history of smoking. The most frequent histological type was adenocarcinoma (ADC) (n = 173, 64.1%), followed by squamous cell carcinoma (SqCC) (n = 76, 28.1%) and large cell neuroendocrine carcinoma (n = 3, 1.1%). Furthermore, there were 18 (6.7%) patients whose histological type could not be classified, such as poorly differentiated carcinoma, adenosquamous carcinoma, pleomorphic carcinoma, and carcinoma not otherwise specified. Regarding molecular subtypes, 64 (23.7%) and six (2.2%) patients exhibited an \textit{EGFR} mutation and \textit{ALK} rearrangement, respectively.

Among the patients, 74 (27.4%) had synchronous brain metastasis at diagnosis. No difference was observed regarding sex, age, and smoking status between the patients with or without synchronous brain metastasis, but there was a significant difference in terms of histologic subtype. The rate of ADC was higher in patients with brain metastasis, whereas the rate of SqCC was higher in patients without brain metastasis. The detailed information about the baseline characteristics of all patients are summarized in Table 1.

PD-L1 expression and synchronous brain metastasis

Of the total study population, positive PD-L1 expression was observed in 181 (67.0%) patients, whereas the remaining 89 patients exhibited negative PD-L1 staining. The prevalence of various PD-L1 TPS ranges was as follows: 0%: 89/270 (33.0%); 1%–9%: 57/270 (21.1%); 10%–49%: 47/270 (17.4%); and ≥50%: 77/270 (28.5%) (Table 1). Compared with PD-L1-negative patients, the proportion of patients with synchronous brain metastasis was significantly higher in PD-L1-positive patients (31.5% vs. 19.1%, \( p = 0.045 \)). The higher incidence of synchronous brain metastasis in PD-L1-positive patients was also observed when analyzed in two different histological subgroups, non-SqCC (n = 194) and SqCC (n = 76). No statistical significance was observed in the SqCC group, with 18.6% and 5.9% incidence of synchronous brain metastasis in PD-L1-positive and PD-L1-negative patients, respectively (\( p = 0.279 \)). For non-SqCC patients, 37.7% of PD-L1-positive patients and 22.2% of PD-L1-negative patients were found to have synchronic brain metastasis, thus confirming a significant difference (\( p = 0.038 \)) (Table 2).

Using univariate logistic regression analysis, non-SqCC histological type and positive PD-L1 expression were identified as factors associated with synchronous brain metastasis in NSCLC patients. Multivariate analysis with other covariates including gender, age, smoking status, and molecular subtypes also showed that two factors, non-SqCC

| Covariates       | Univariable      | Multivariable (full) | Multivariable (backward elimination) |
|------------------|-------------------|----------------------|-------------------------------------|
| Gender           |                   |                      |                                     |
| Female           | Ref               | Ref                  | –                                   |
| Male             | 0.76 (0.43–1.35)  | 1.30 (0.62–2.75)     | –                                   |
| Age at diagnosis | 0.99 (0.96–1.02)  | 0.98 (0.95–1.01)     | –                                   |
| Smoking          |                   |                      |                                     |
| Never smoker     | Ref               | Ref                  | –                                   |
| Smoker (ex- or current-) | 0.63 (0.37–1.08)  | 0.57 (0.28–1.16)     | –                                   |
| Histology        |                   |                      |                                     |
| SqCC             | Ref               | Ref                  | –                                   |
| Non-SqCC         | 2.51 (1.30–5.18)  | 2.63 (1.29–5.69)     | 2.84 (1.46–5.95)                    |
| \textit{EGFR} mutation |           |                      |                                     |
| WT or NA         | Ref               | Ref                  | –                                   |
| \textit{EGFR}-mutated | 1.70 (0.93–3.09)  | 1.19 (0.58–2.41)     | –                                   |
| \textit{ALK} rearrangement | | | |
| WT or NA         | Ref               | Ref                  | –                                   |
| \textit{ALK}-rearranged | 0.52 (0.03–3.32)  | 0.31 (0.02–2.15)     | –                                   |
| PD-L1 expression |                   |                      |                                     |
| PD-L1 negative   | Ref               | Ref                  | –                                   |
| PD-L1 positive   | 1.95 (1.07–3.68)  | 2.42 (1.30–4.69)     | 2.24 (1.22–4.30)                    |

Abbreviations: ALK, anaplastic lymphoma kinase; CI, confidence interval; EGFR, epidermal growth factor receptor; NA, not available; OR, odds ratio; PD-L1, programmed death-ligand 1; Ref, reference; SqCC, squamous cell carcinoma; WT, wild-type.
subtype (OR: 2.84, 95% CI: 1.41-5.72, \( p = 0.003 \)) and positive PD-L1 expression (OR: 2.24, 95% CI: 1.20-4.21, \( p = 0.012 \)), were independent risk factors with a high probability of brain metastasis at the time of NSCLC diagnosis (Table 3).

**PD-L1 expression and CNS progression**

The median follow-up time for all patients in this study was 27.35 (95% CI: 24.99-29.71) months. A total of 43 patients experienced CNS progression during the study period, including two cases of leptomeningeal seeding. The time to CNS progression was not different based on PD-L1 positivity. The two-year cumulative CNS progression incidence rates were 26.3% and 28.4% in PD-L1-positive and PD-L1-negative patients, respectively (log rank \( p = 0.944 \)) (Figure 1a). Differences in CNS progression were not evident even when the patients were analyzed in two different subgroups depending on the presence or absence of synchronous brain metastasis at diagnosis (Figure 1b,c). Of note, there was also no difference in CNS progression according to the histologic subtypes SqCC and non-SqCC (Figure S1).

**Survival outcomes in patients with synchronous brain metastasis**

Of the 74 patients with synchronous brain metastasis, 57 (77.0%) received local treatment for their brain lesions in addition to systemic therapy for NSCLC. The most frequently applied treatment was gamma knife radiosurgery (GKRS) (\( n = 38 \)), followed by whole-brain radiotherapy (WBRT) (\( n = 18 \)) and surgical resection (\( n = 4 \)). Of these, two patients received WBRT following GKRS, and one patient received GKRS following resection. The application rate of local treatment for brain metastasis did not differ between PD-L1-positive and PD-L1-negative patients (78.9% vs. 70.6%, \( p = 0.518 \)). The median OS of the
patients with synchronous brain metastasis was 16.11 (95% CI: 9.46–22.76) months, and no significant difference was observed between PD-L1-positive and PD-L1-negative patients (17.62 vs. 15.06 months, \( p = 0.592 \)) (Figure 2a). Meanwhile, about a third of patients (\( n = 27, 36.5\% \)) received immuno-oncology (IO) therapies during their treatment course; patients who received IO therapy showed significantly longer OS than who did not (not reached vs. 9.86 months, \( p = 0.004 \)) (Figure 2b).

**DISCUSSION**

In the present study, we evaluated the significance of PD-L1 expression including its association with early brain metastasis and its clinical impact on CNS progression and survival in patients with NSCLC. Patients with tumors exhibiting positive PD-L1 expression (TPS \( \geq 1\% \)) were found to have a higher frequency and risk of synchronous brain metastasis when diagnosed with advanced NSCLC. However, no prognostic impact of positive PD-L1 expression was observed on either CNS progression in the entire cohort of patients or OS in patients presenting with synchronous brain metastasis. It is already known that nonsquamous histology is one risk factor for the development of brain metastasis in NSCLC, and EGFR/ALK-mutated NSCLC exhibits a significantly higher incidence of brain metastasis. On the basis of these results, we performed a multivariate analysis including histology and molecular tumor type, and positive PD-L1 expression was analyzed as an independent factor in the occurrence of brain metastasis at initial presentation for patients with NSCLC.

The basic principle for the relationship between PD-L1 expression and synchronous brain metastasis has not been elucidated. To metastasize to other organs, tumor cells must avoid recognition and destruction by the host immune system during their journey through the hematological and lymphatic circulation and adapt to the new environment of the distant site. The long-held CNS immune privilege paradigm, consisting of the presence of the blood–brain barrier (BBB) and the absence of a classic lymphatic drainage system, has become obsolete following the discovery of a lymphatic system in the CNS and the ability of T cells to cross the BBB. Studies have revealed that the brain has an idiosyncratic immune environment that maintains homeostasis and curbs inflammatory responses that may otherwise be harmful. Current data suggest that various immunosuppressive factors contribute toward this unique environment in the brain including regulatory T (Treg) cells and suppressor T cell activity. To date, the well-studied PD-L1/PD-1 axis determines physiological immune homeostasis and suppresses the T cell activity in various ways including inhibiting T cell survival, proliferation, cytokine production, and other effector functions. Intratumoral PD-L1 expression has been considered to be an indirect measure of locally suppressed antitumor immunity. Jacobs et al. demonstrated the important role of the PD-L1/PD-1 pathway in malignant, but not benign, human brain tumors. In response to this localized effect, the tumor may further affect the brain environment by inhibiting the overall immune response. Li et al. demonstrated a systemic immunosuppressive state in patients with brain metastatic NSCLC, showing increased peripheral myeloid cell PD-L1 expression correlating with decreased T cell activity. Thus, decreased T cell function, which could be inferred from PD-L1 expression, may render the brain more vulnerable to metastatic disease. Therefore, previous reports that PD-L1 overexpression is associated with poor survival for NSCLC patients may result from the high incidence of synchronous brain metastasis, which is a poor prognostic factor and is consistent with the results of our study. Hence, a more careful examination may be required to monitor brain metastasis during staging workups when patients are diagnosed with PD-L1-positive NSCLC.

The prognostic impact of PD-L1 expression in NSCLC for CNS progression was not observed in this study. However, since the course of disease varied depending on response to treatment and brain lesions were particularly affected by local therapies, it would be difficult to prove the relationship between the PD-L1 expression and CNS-related survival from our results. Of note, previous studies reported significant intracranial activity of IO agents in various trials, and recently published phase II data indicated that pembrolizumab was effective against brain metastases from NSCLC patients with PD-L1 expression of at least 1%. This desired effect of IO treatment on survival improvement for NSCLC patients with brain metastasis was observed in our study as well, but it should be taken into account that patients received IO treatment during different courses of chemotherapy and CNS response data were lacking. Future well-organized studies are necessary to establish the clinical significance of PD-L1 expression on CNS-related survival and OS in patients with NSCLC.

To our knowledge, this is the first study to suggest that PD-L1 expression in NSCLC may be associated with early brain metastasis. The majority of early IO clinical trials included fewer patients with brain metastasis, and sufficient data were not available for these patients. Our finding lays the groundwork for future research into the link between early brain metastasis and the PD-1/PD-L1 axis.

This study has several limitations that should be considered. The single-center retrospective design is a well-known weakness associated with various types of bias. Another limitation is that the results from only one antibody were used for evaluating PD-L1 expression. There are four standardized PD-L1 IHC assays using different antibodies: 22C3 and 28–8 pharmDX assays on Dako platforms and SP142/SP263 on Ventana platforms. Many concerns have been raised about the compatibility of the results from these different methods. However, high concordance between the results from Dako 28–8, Dako 22C3, and Ventana SP263 assays was demonstrated, and Adam et al. showed that clone SP263 had a unique ability in yielding concordant
results across all centers and platforms.\textsuperscript{36} Therefore, our results obtained using SP263 are likely representative, widely applicable, and reliable.

In conclusion, a significant association between PD-L1 expression and synchronous brain metastasis in NSCLC, especially for non-SqCC, was found in this study. Although spatial tumor heterogeneity should always be considered in metastatic disease, this finding denotes that patients diagnosed with PD-L1-positive NSCLC may need a closer examination for the likelihood of accompanying brain metastasis. Future prospective, controlled studies with a large patient population are needed to validate this finding. The precise mechanism underlying the relationship between PD-L1 expression and brain metastasis remains to be elucidated.

ACKNOWLEDGMENTS
This research was funded by Korea University, Seoul, Republic of Korea (Grant number K1609621).

CONFLICT OF INTEREST
The authors declare that they have no competing interests.

ORCID
Kyoungmin Lee \textsuperscript{a} https://orcid.org/0000-0002-6578-7671
Eun J. Kang \textsuperscript{a} https://orcid.org/0000-0003-0702-3400

REFERENCES
1. Brown NA, Aisner DL, Oxnard GR. Precision medicine in non-small cell lung cancer: current standards in pathology and biomarker interpretation. Am Soc Clin Oncol Educ Book. 2018;38:708–15.
2. Riess JW, Wakelee HA. Metastatic non-small cell lung cancer management: novel targets and recent clinical advances. Clin Adv Hematol Oncol. 2012;10(4):226–34.
3. Edlund K, Madjar K, Mattsson JSM, Djureinovic D, Lindskog C, Brunström H, et al. Prognostic impact of tumor cell programmed death ligand 1 expression and immune cell infiltration in NSCLC. J Thorac Oncol. 2019;14(4):628–40.
4. Wang X, Teng F, Kong L, Yu J. PD-L1 expression in human cancers and its association with clinical outcomes. Onco Targets Ther. 2016;9:5023–39.
5. Pawelczyk K, Piotrowska A, Ciesielska U, Jabłonska K, Gletzel-Plucińska N, Grzegorzka J, et al. Role of PD-L1 expression in non-small cell lung cancer and their prognostic significance according to clinicopathological factors and diagnostic markers. Int J Mol Sci. 2019;20(4):824. https://doi.org/10.3390/ijms20040824.
6. Wang A, Wang HY, Liu Y, Zhao MC, Zhang HJ, Lu ZY, et al. The prognostic value of PD-L1 expression for non-small cell lung cancer patients: a meta-analysis. Eur J Surg Oncol. 2015;41(4):450–6.
7. Zhou Q, PC09.01 debate 1: Early vs Delayed treatment of asymptomatic brain metastases in wild-type NSCLC - early. J Thorac Oncol. 2018;13(10):S251.
8. Sperduto PW. Prognostic classification systems for brain metastases. In: Chang EL, Brown PD, Lo SS, Sahgal A, Sub J, editors. Adult CNS Radiation Oncology: Principles and Practice. Cham: Springer; 2018. p. 419–30.
9. Lim JH, Um SW. The risk factors for brain metastases in patients with non-small cell lung cancer. Ann Transl Med. 2018;6(suppl 1):S66.
10. Gaspar LE, Chansky K, Albain KS, Vallieres E, Rusch V, Crowley JJ, et al. Time from treatment to subsequent diagnosis of brain metastases in stage III non-small-cell lung cancer: a retrospective review by the Southwest Oncology Group. J Clin Oncol. 2005;23(13):2955–61.
31. Rebelatto MC, Midha A, Mistry A, Sabalos C, Schechter N, Li X, et al. Development of a programmed cell death ligand-1 immunohistochemical assay validated for analysis of non-small cell lung cancer and head and neck squamous cell carcinoma. Diagn Pathol. 2016;11(1):95.

32. Jotatsu T, Oda K, Yatera K. PD-L1 immunohistochemistry in patients with non-small cell lung cancer. J Thorac Dis. 2018;10(suppl 18):S2127–S9.

33. Hirsch FR, McElhinny A, Stanforth D, Ranger-Moore J, Jansson M, Kulangara K, et al. PD-L1 immunohistochemistry assays for lung cancer: results from phase 1 of the blueprint PD-L1 IHC assay comparison project. J Thorac Oncol. 2017;12(2):208–22.

34. Rimm DL, Han G, Taube JM, Yi ES, Bridge JA, Flieder DB, et al. A prospective, multi-institutional, pathologist-based assessment of 4 immunohistochemistry assays for PD-L1 expression in non-small cell lung cancer. JAMA Oncol. 2017;3(8):1051–8.

35. Ratcliffe MJ, Sharpe A, Midha A, Barker C, Scott M, Sorer P, et al. Agreement between programmed cell death ligand-1 diagnostic assays across multiple protein expression cutoffs in non-small cell lung cancer. Clin Cancer Res. 2017;23(14):3585–91.

36. Adam J, Le Stang N, Rouquette I, Cazes A, Badoual C, Pinot-Roussel H, et al. Multicenter harmonization study for PD-L1 IHC testing in non-small-cell lung cancer. Ann Oncol. 2018;29(4):953–8.

SUPPORTING INFORMATION
Additional supporting information may be found online in the Supporting Information section at the end of this article.

How to cite this article: Lee K, Choi YJ, Kim JS, et al. Association between PD-L1 expression and initial brain metastasis in patients with non-small cell lung cancer and its clinical implications. Thorac Cancer. 2021;1–8. https://doi.org/10.1111/1759-7714.14006